Literature DB >> 27595298

Comparison of Saffron versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial.

L Kashani1, S Eslatmanesh2, N Saedi3, N Niroomand3, M Ebrahimi3, M Hosseinian4, T Foroughifar5, S Salimi5, S Akhondzadeh2.   

Abstract

Introduction: Postpartum depression is a common mental health problem that is associated with maternal suffering. The aim of this double-blind clinical trial was to compare safety and efficacy of saffron and fluoxetine in treatment of mild to moderate postpartum depression.
Methods: This was a 6-week, double-blind, randomized clinical trial. Subjects were women aged 18-45 years with mild to moderate postpartum depression who had Hamilton Depression Rating Scale (HDRS 17-item) score≤18. Eligible participants were randomized to receive either a capsule of saffron (15 mg capsule) or fluoxetine (20 mg capsule) twice daily for 6 weeks. The primary outcome measure was to evaluate efficacy of saffron compared to fluoxetine in improving depressive symptoms (HDRS score).
Results: There was no significant effect for time×treatment interaction on HDRS score [F (4.90, 292.50)=1.04, p=0.37] between the 2 groups. 13 (40.60%) patients in the saffron group experienced complete response (≥50% reduction in HDRS score) compared with 16 (50%) in the fluoxetine group and the difference between the 2 groups was not significant in this regard (p=0.61). Frequency of adverse events was not significantly different between the treatment groups. Discussion: The results of this study may suggest that saffron is a safe alternative medication for improving depressive symptoms of postpartum depression. Nevertheless, it should be mentioned that the trial is not well powered and should be considered a preliminary study. Therefore, large clinical trials with longer treatment periods and comparison with placebo group would be appropriate for future studies. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27595298     DOI: 10.1055/s-0042-115306

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  12 in total

Review 1.  Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.

Authors:  Ariela Frieder; Madeleine Fersh; Rachel Hainline; Kristina M Deligiannidis
Journal:  CNS Drugs       Date:  2019-03       Impact factor: 5.749

Review 2.  Development of neuroactive steroids for the treatment of postpartum depression.

Authors:  Handan Gunduz-Bruce; Koji Takahashi; Ming-Yi Huang
Journal:  J Neuroendocrinol       Date:  2021-08-30       Impact factor: 3.870

Review 3.  Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management.

Authors:  Amjad M Husaini; Khan Nadiya Jan; Gowher A Wani
Journal:  Heliyon       Date:  2021-05-14

4.  Antidepressant treatment for postnatal depression.

Authors:  Jennifer Valeska Elli Brown; Claire A Wilson; Karyn Ayre; Lindsay Robertson; Emily South; Emma Molyneaux; Kylee Trevillion; Louise M Howard; Hind Khalifeh
Journal:  Cochrane Database Syst Rev       Date:  2021-02-13

5.  Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind Randomized Clinical Trial.

Authors:  Sophia Esalatmanesh; Mojtaba Biuseh; Ahmad Ali Noorbala; Seyed-Ali Mostafavi; Farzin Rezaei; Bita Mesgarpour; Payam Mohammadinejad; Shahin Akhondzadeh
Journal:  Iran J Psychiatry       Date:  2017-07

6.  Evaluation of the effectiveness of crocin isolated from saffron in treatment of burning mouth syndrome: A randomized controlled trial.

Authors:  Atessa Pakfetrat; Mehdi Talebi; Zohreh Dalirsani; Ahmad Mohajeri; Roya Zamani; Ala Ghazi
Journal:  Avicenna J Phytomed       Date:  2019 Nov-Dec

7.  Using Matching-Adjusted Indirect Comparisons and Network Meta-analyses to Compare Efficacy of Brexanolone Injection with Selective Serotonin Reuptake Inhibitors for Treating Postpartum Depression.

Authors:  Miranda C Cooper; Hannah S Kilvert; Paul Hodgkins; Neil S Roskell; Adi Eldar-Lissai
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

8.  Antianhedonic and Antidepressant Effects of Affron®, a Standardized Saffron (Crocus Sativus L.) Extract.

Authors:  Laura Orio; Francisco Alen; Antonio Ballesta; Raquel Martin; Raquel Gomez de Heras
Journal:  Molecules       Date:  2020-07-15       Impact factor: 4.411

9.  Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial.

Authors:  Mansoor Shakiba; Ehsan Moazen-Zadeh; Ahmad Ali Noorbala; Morteza Jafarinia; Parisa Divsalar; Ladan Kashani; Nazila Shahmansouri; Abbas Tafakhori; Hannaneh Bayat; Shahin Akhondzadeh
Journal:  Avicenna J Phytomed       Date:  2018 Nov-Dec

10.  Efficacy of transcranial magnetic stimulation and fluoxetine in the treatment of postpartum depression: A protocol for systematic review and meta-analysis.

Authors:  Yan-Jun Guo; Yong-Ming Shan; Zhi-Jian Wang; Zhong-Fei Shen
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.